A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Friday 18 March 2011

Norwegian valsartan ruling: now in English too

Earlier this month The SPC Blog posted this information concerning the ruling of the Oslo District Court on 10 February that Actavis’ valsartan/HCTZ product infringed Novartis’ Norwegian process patent NO 304 023 for a route of synthesis for valsartan as well as SPC/NO 1998 024. The judgment, which is now under appeal, was handed down on 10 February 2011; it deals inter alia with the question of the scope of Novartis’ Norwegian SPC in relation to valsartan (SPC/NO 1998 024).

Gunnar Sørlie (Partner, Bugge, Arentz-Hansen & Rasmussen) has now kindly sent this weblog a transcript of the original decision (in Norwegian) together with an unofficial translation into English. The SPC Blog thanks him very much for his kindness.

No comments: